Strong Cash Position
Spectral AI's cash balance remained flat at $10.5 million from the second quarter of 2025, with an additional $7.6 million from a registered direct offering, ensuring sufficient financing for the foreseeable future.
FDA Submission Progress
The FDA submission for the DeepView system was completed in June 2025, marking a significant milestone. Despite the U.S. government shutdown, interactions with the FDA on the de novo application are ongoing.
Positive International Feedback
Units placed in international markets have received overwhelmingly positive feedback, highlighting ease of use and effectiveness, with plans to incorporate feedback into future iterations.
Development of Handheld Device
Progress is being made on the handheld module for military and civilian applications, with positive feedback from the military and potential for future support.